Iteos Therapeutics Stock Filter Stocks by Fundamentals
ITOS Stock | USD 10.13 0.13 1.27% |
Fundamental analysis of Iteos Therapeutics allows traders to better anticipate movements in Iteos Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
All Next | Launch Module |
Iteos Fundamentals
Return On Equity | -0.24 | ||||
Return On Asset | -0.15 | ||||
Operating Margin | (4.28) % | ||||
Current Valuation | (122.63 M) | ||||
Shares Outstanding | 38.27 M | ||||
Shares Owned By Insiders | 1.13 % | ||||
Shares Owned By Institutions | 98.87 % | ||||
Number Of Shares Shorted | 2.83 M | ||||
Price To Earning | 50.50 X | ||||
Price To Book | 0.70 X | ||||
Price To Sales | 11.22 X | ||||
Revenue | 35 M | ||||
Gross Profit | 35 M | ||||
EBITDA | (159.53 M) | ||||
Net Income | (134.41 M) | ||||
Cash And Equivalents | 791.86 M | ||||
Cash Per Share | 22.26 X | ||||
Total Debt | 5.1 M | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 6.42 X | ||||
Book Value Per Share | 14.72 X | ||||
Cash Flow From Operations | (98.18 M) | ||||
Short Ratio | 1.04 X | ||||
Earnings Per Share | (3.05) X | ||||
Target Price | 11.0 | ||||
Number Of Employees | 173 | ||||
Beta | 1.52 | ||||
Market Capitalization | 392.69 M | ||||
Total Asset | 686.98 M | ||||
Retained Earnings | (9.78 M) | ||||
Working Capital | 469.18 M | ||||
Net Asset | 686.98 M |
About Iteos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iteos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iteos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iteos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.